Black Diamond Therapeutics (BDTX) Short Interest Ratio & Short Volume → Move Your Money Before May 22 (From Stansberry Research) (Ad) Free BDTX Stock Alerts $5.89 +0.78 (+15.26%) (As of 04/26/2024 ET) Add Compare Share Share Short InterestStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial Media Black Diamond Therapeutics Short Interest DataCurrent Short Volume1,760,000 sharesPrevious Short Volume2,040,000 sharesChange Vs. Previous Month-13.73%Dollar Volume Sold Short$9.19 millionShort Interest Ratio / Days to Cover2.8Last Record DateApril 15, 2024Outstanding Shares51,720,000 sharesPercentage of Shares Shorted3.40%Today's Trading Volume565,162 sharesAverage Trading Volume577,258 sharesToday's Volume Vs. Average98% Short Selling Black Diamond Therapeutics ? Sign up to receive the latest short interest report for Black Diamond Therapeutics and its competitors with MarketBeat's FREE newsletter. Email Address Skip Charts & View Short Interest HistoryShort InterestDays to CoverShort Percent of FloatBDTX Short Interest Over TimeBDTX Days to Cover Over TimeBDTX Percentage of Float Shorted Over Time Ad Stansberry ResearchMove Your Money Before May 1Did you know that the IRS has allegedly been using AI to spy on the bank accounts of American citizens? Click here to get the full story before May 1. Black Diamond Therapeutics Short Interest History Export to ExcelReport DateTotal Shares Sold ShortDollar Volume Sold ShortChange from Previous ReportPercentage of Float ShortedDays to CoverPrice on Report Date 4/15/20241,760,000 shares $9.19 million -13.7%N/A2.8 $5.22 3/31/20242,040,000 shares $10.34 million +12.7%N/A3.4 $5.07 3/15/20241,810,000 shares $8.67 million +1.7%N/A3.1 $4.79 2/29/20241,780,000 shares $9.16 million -5.3%N/A3.1 $5.15 2/15/20241,880,000 shares $9.51 million -21.7%N/A3.5 $5.06 1/31/20242,400,000 shares $9.22 million -33.0%N/A4.5 $3.84 Get the Latest News and Ratings for BDTX and Related StocksEnter your email address below to receive the latest news and analysts' ratings for Black Diamond Therapeutics and its competitors with MarketBeat's FREE daily newsletter. 1/15/20243,580,000 shares $10.67 million -1.1%N/A7.9 $2.98 12/31/20233,620,000 shares $10.17 million -0.6%N/A7.1 $2.81 12/15/20233,640,000 shares $9.86 million +6.4%N/A7 $2.71 11/30/20233,420,000 shares $8.00 million +1.8%N/A6.2 $2.34 11/15/20233,360,000 shares $7.56 million +0.3%N/A6 $2.25 10/31/20233,350,000 shares $6.30 million +12.8%9.8%6.2 $1.88 10/15/20232,970,000 shares $6.80 million +24.3%8.7%5.6 $2.29 9/30/20232,390,000 shares $6.86 million +68.3%7.0%3.9 $2.87 9/15/20231,420,000 shares $5.04 million +24.6%4.1%0.3 $3.55 8/31/20231,140,000 shares $3.84 million +7.6%3.2%0.3 $3.37 8/15/20231,060,000 shares $3.36 million +1.9%2.9%0.3 $3.17 7/31/20231,040,000 shares $3.88 million -67.3%4.7%0.3 $3.73 7/15/20233,180,000 shares $15.42 million -38.4%14.4%0.8 $4.85 6/30/20235,160,000 shares $26.06 million +166.0%23.4%1.3 $5.05 6/15/20231,940,000 shares $4.07 million No Change8.4%31.3 $2.10 5/31/20231,940,000 shares $3.61 million No Change8.4%22.7 $1.86 5/15/20231,940,000 shares $3.74 million -1.5%8.4%24.1 $1.93 4/30/20231,970,000 shares $2.82 million No Change8.6%24.1 $1.43 4/15/20231,970,000 shares $2.94 million -1.5%8.6%22.6 $1.49 3/31/20232,000,000 shares $3.78 million -1.5%8.7%17.3 $1.89 3/15/20232,030,000 shares $3.41 million +3.1%8.8%13.5 $1.68 2/28/20231,970,000 shares $3.49 million -1.0%8.6%14.6 $1.77 2/15/20231,990,000 shares $5.23 million No Change8.7%14.6 $2.63 1/31/20231,990,000 shares $5.97 million -2.0%8.7%13.3 $3.00 1/15/20232,030,000 shares $5.36 million -2.4%8.9%9.6 $2.64 12/30/20222,080,000 shares $3.74 million +5.6%9.1%10 $1.80 12/15/20221,970,000 shares $2.96 million No Change8.6%10.5 $1.50 11/30/20221,970,000 shares $4.16 million -2.5%8.6%11.1 $2.11 11/15/20222,020,000 shares $4.79 million -2.4%8.8%11.2 $2.37 10/31/20222,070,000 shares $4.78 million -7.2%9.1%11.3 $2.31 10/15/20222,230,000 shares $2.83 million +6.2%9.8%14.9 $1.27 9/30/20222,100,000 shares $3.55 million No Change9.2%15.8 $1.69 9/15/20222,100,000 shares $5.50 million -3.7%9.2%11.1 $2.62 8/31/20222,180,000 shares $6.95 million -0.5%9.5%10.7 $3.19Move Your Money Before May 22 (Ad)The SIX WORDS That Could Destroy America... And The Value of Your Savings. He predicted the dangerous rise of inflation... the death of the 60/40 portfolio... and now, this 40-year market veteran and retirement expert is stepping forward with a new must-see warning for every American. It involves the world's most powerful investors, central bankers, and America's most bitter geopolitical rivals. Here's where Dr. David Eifrig says to move your money immediately. BDTX Short Interest - Frequently Asked Questions What is Black Diamond Therapeutics' current short interest? Short interest is the volume of Black Diamond Therapeutics shares that have been sold short but have not yet been covered or closed out. As of April 15th, investors have sold 1,760,000 shares of BDTX short. Learn More on Black Diamond Therapeutics' current short interest. What is a good short interest ratio for Black Diamond Therapeutics? The short interest ratio, also known as the "days to cover ratio", is calculated by dividing the number of shares of a stock sold short divided by its average trading volume. A short interest ratio ranging between 1 and 4 generally indicates strong positive sentiment about a stock and a lack of short sellers. A short interest ratio of 10 or greater indicates strong pessimism about a stock. BDTX shares currently have a short interest ratio of 3.0. Learn More on Black Diamond Therapeutics's short interest ratio. Which institutional investors are shorting Black Diamond Therapeutics? As of the most recent reporting period, the following institutional investors, funds, and major shareholders have reported short positions of Black Diamond Therapeutics: Concourse Financial Group Securities Inc., and Simplex Trading LLC. These positions are disclosed in Form 13F filings with the Securities and Exchange Commission. Is Black Diamond Therapeutics' short interest increasing or decreasing? Black Diamond Therapeutics saw a decline in short interest in April. As of April 15th, there was short interest totaling 1,760,000 shares, a decline of 13.7% from the previous total of 2,040,000 shares. Changes in short volume can be used to identify positive and negative investor sentiment. Investors that short sell a stock are betting that its price will decline in the future. An increase in short sale volume suggests bearish (negative) sentiment among investors. A decrease on short sale volume suggests bullish (positive) sentiment. How does Black Diamond Therapeutics' short interest compare to its competitors? Here is how the short interest of companies in the sector of "medical" compare to Black Diamond Therapeutics: Fennec Pharmaceuticals Inc (8.08%), Invivyd, Inc. (7.05%), Coherus BioSciences, Inc. (18.97%), Monte Rosa Therapeutics, Inc. (5.91%), Sutro Biopharma, Inc. (3.49%), Adverum Biotechnologies, Inc. (7.54%), Anavex Life Sciences Corp. (26.81%), Elevation Oncology, Inc. (13.03%), Compass Therapeutics, Inc. (1.88%), Poseida Therapeutics, Inc. (6.55%), Which stocks are the most shorted right now? As of the most recent reporting period, the following stocks had the largest short interest positions: T-Mobile US, Inc. ($3.70 billion), Occidental Petroleum Co. ($3.52 billion), Charter Communications, Inc. ($3.14 billion), General Motors ($2.68 billion), Coinbase Global, Inc. ($2.57 billion), Moderna, Inc. ($2.18 billion), Tractor Supply ($2.10 billion), Royal Caribbean Cruises Ltd. ($1.91 billion), TC Energy Co. ($1.90 billion), and Williams-Sonoma, Inc. ($1.78 billion). View all of the most shorted stocks. What does it mean to sell short Black Diamond Therapeutics stock? Short selling BDTX is an investing strategy that aims to generate trading profit from Black Diamond Therapeutics as its price is falling. BDTX shares are trading up $0.78 today. To short a stock, an investor borrows shares, sells them and buys the shares back on the public market later to return it to the lender. Short sellers are betting that a stock will decline in price. If the stock does drop after selling, the short seller buys it back at a lower price and returns it to the lender. The difference between the sell price and the buy price is the trader's profit. How does a short squeeze work against Black Diamond Therapeutics? A short squeeze for Black Diamond Therapeutics occurs when it has a large amount of short interest and its stock increases in price. This forces short sellers to cover their short interest positions by buying actual shares of BDTX, which in turn drives the price of the stock up even further. How often is Black Diamond Therapeutics' short interest reported? Short interest is typically published by a stock exchange once per month. However, NASDAQ publishes a report for U.S. stocks, including BDTX, twice per month. The most recent reporting period available is April, 15 2024. More Short Interest Resources from MarketBeat Related Companies: Fennec Pharmaceuticals Short Squeeze Invivyd Short Squeeze Coherus BioSciences Short Squeeze Monte Rosa Therapeutics Short Squeeze Sutro Biopharma Short Squeeze Adverum Biotechnologies Short Squeeze Anavex Life Sciences Short Squeeze Elevation Oncology Short Squeeze Compass Therapeutics Short Squeeze Poseida Therapeutics Short Squeeze Short Interest Tools: Stocks to Short Largest Short Interest Positions Short Interest Increases Short Interest Decreases Short Interest Reporting Dates This page (NASDAQ:BDTX) was last updated on 4/26/2024 by MarketBeat.com Staff From Our PartnersThese AI trades triggered this morning (545% return)Prosper Trading AcademyConflict In Israel Sends Gold Soaring ???? Here’s How To Get Your ShareColonial MetalsExposed: 10 CENT Crypto to Explode April 20th?True Market InsidersHe Is Giving Away BitcoinCrypto Swap ProfitsThe A.I. story nobody is telling you (Read ASAP)TradeSmithFed launches fourth dollar overhaulStansberry ResearchMan Who Predicted 2008: “This Will be Worse.”AltimetryJeff Bezos Just Humiliated Elon MuskInvestorPlace